Creo Medical Group (LON:CREO) Stock Price Down 2.2% – Should You Sell?

Creo Medical Group PLC (LON:CREO)’s share price fell 2.2% during mid-day trading on Thursday . The stock traded as low as GBX 11.75 and last traded at GBX 11.86. 143,598 shares were traded during mid-day trading, a decline of 83% from the average session volume of 858,061 shares. The stock had previously closed at GBX 12.13.

Creo Medical Group Trading Down 2.2%

The business’s 50 day moving average price is GBX 14.28 and its 200-day moving average price is GBX 12.12. The company has a market cap of £48.93 million, a price-to-earnings ratio of -11.86 and a beta of 0.56. The company has a debt-to-equity ratio of 6.90, a quick ratio of 2.19 and a current ratio of 5.28.

Insider Activity

In other Creo Medical Group news, insider Richard John Rees purchased 8,036 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was purchased at an average price of GBX 11 per share, with a total value of £883.96. Also, insider Craig Jonathan Gulliford purchased 8,036 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were acquired at an average price of GBX 11 per share, with a total value of £883.96. Corporate insiders own 4.11% of the company’s stock.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.